Sign in

CIK 0001710072

  • Large accelerated filer

Edgewise Therapeutics, Inc.

Sign in to watch
Ticker
EWTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
821725586
Phone
+1 720-262-7002
Business address
1715 38TH ST, BOULDER, CO, 80301
  1. 4 Grant or award Director acquired 559 shares (grant or award)
  2. 4 Planned sale Chief Scientific Officer sold 200 shares at $30.02 ($6,004)
  3. 4 Planned sale President and CEO sold 100 shares at $30.00 ($3,000)
  4. 4 Planned sale Chief Scientific Officer sold 9,215 shares at an average $30.04 ($276,776)
  5. 4 Planned sale President and CEO sold 9,536 shares at an average $30.13 ($287,316)
  6. 4 Open-market sale Chief Business Officer sold 10,000 shares at $30.03 ($300,300)
  7. 4 Planned sale CMO sold 25,000 shares at $27.63 ($690,658)
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Planned sale Chief Scientific Officer sold 100,000 shares at $27.37 ($2,737,470)
  11. 4 Planned sale Chief Development Officer sold 29,709 shares at an average $29.69 ($881,915)
  12. 4 Exercise or conversion Chief Financial Officer acquired 70,000 shares (option exercise)
  13. 4 Open-market sale Chief Scientific Officer sold 75,000 shares at an average $28.27 ($2,120,101)
  14. 4 Open-market sale General Counsel sold 70,922 shares at an average $28.15 ($1,996,574)
  15. 4 Open-market sale CMO sold 7,162 shares at $28.29 ($202,603)
  16. 4 Open-market sale Chief Business Officer sold 42,068 shares at $29.03 ($1,221,133)
  17. 4 Open-market sale Chief Financial Officer sold 125,092 shares at an average $28.57 ($3,573,980)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 4 of 11 · 203 filings